Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is making significant progress in its clinical trials for gedatolisib, with completed enrollment in the Phase 3 VIKTORIA-1 trial and ongoing trials for HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer. The addition of Study 2 in the VIKTORIA-2 trial expands Celcuity's potential TAM to nearly all newly diagnosed US patients, and the subcutaneous formulation presents a potential evergreening opportunity. Positive topline results from the VIKTORIA-1 trial, reporting significant PFS improvements, suggest the potential for gedatolisib to become a top choice for patients in the second-line and beyond setting, and forecasted peak sales of around $4.5 billion could result in a significant increase in equity value and support a Buy rating.

Bears say

Celcuity is projected to have a negative net income for the foreseeable future and may require additional funding to continue their clinical trials. There is also no guarantee that the company will be able to secure favorable financing or partnerships. However, the recent positive results from the VIKTORIA-1 trial and upcoming ASCO presentation could potentially increase the company's value and addressable market for its lead candidate gedatolisib. Overall, there are some potential risks and uncertainties for Celcuity's future, but the positive results and potential market expansion make the company one to watch.

Celcuity (CELC) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $139.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $139.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.